High 15-F2t-Isoprostane Levels in Patients with a Previous History of Nonmelanoma Skin Cancer: The Effects of Supplementary Antioxidant TherapyReportar como inadecuado

High 15-F2t-Isoprostane Levels in Patients with a Previous History of Nonmelanoma Skin Cancer: The Effects of Supplementary Antioxidant Therapy - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BioMed Research International - Volume 2015 2015, Article ID 963569, 8 pages -

Clinical Study

Department of Nutrition, Federal University of Piauí UFPI, Campus Universitário Ministro Petrônio Portella, 64049-550 Teresina, PI, Brazil

School of Medical Sciences FCM, University of Campinas UNICAMP, 13083-887 Campinas, SP, Brazil

Faculty of Pharmaceutical Sciences FCF, University of Campinas UNICAMP, 13083-859 Campinas, SP, Brazil

Department of Biological and Health Science Center, Mackenzie Presbyterian University, 01302-907 São Paulo, SP, Brazil

Received 4 February 2015; Revised 10 May 2015; Accepted 14 May 2015

Academic Editor: Pierre Hainaut

Copyright © 2015 Betânia de Jesus e Silva de Almendra Freitas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Phase I of this study was aimed at comparing the profiles of oxidative stress biomarkers in patients with history of nonmelanoma skin cancer NMSC, previously treated with surgery, to the healthy subjects. Phase II aimed to evaluate the effects of supplementary antioxidant therapy on the levels of biomarkers in the case group. Materials and Methods. In Phase I, oxidative stress biomarkers were measured in blood samples obtained from 24 healthy subjects and 60 patients with history of NMSC previously treated with surgery. In Phase II, the 60 patients with history of NMSC were randomized into two subgroups, one receiving placebo and the other receiving vitamin C, vitamin E, and zinc supplementation for 8 weeks, followed by reevaluation of biomarkers. Results. In Phase I, patients with history of NMSC showed increased plasma concentrations of all biomarkers, but only 15-isoprostane was significantly higher than in the healthy subjects. Risk of NMSC increased by 4% for each additional 1 pg-mL increase in 15-isoprostane. In Phase II, supplementation did not significantly reduce levels of oxidative stress biomarkers. Conclusion. Patients with history of NMSC had significantly high 15-isoprostane plasma levels; supplementation did not result in significant reduction of oxidative stress biomarkers. This trial was registered with ClinicalTrials.gov ID NCT02248584.

Autor: Betânia de Jesus e Silva de Almendra Freitas, Gustavo Rafaini Lloret, Marília Berlofa Visacri, Bruna Taliani Tuan, Lais Samp

Fuente: https://www.hindawi.com/


Documentos relacionados